Dr. Reddy's Laboratories Limited (FRA:RDDA)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.60B -8.7% |
| Revenue (ttm) | 3.03B -3.6% |
| Net Income | 257.03M -52.3% |
| EPS | 0.32 -52.2% |
| Shares Out | n/a |
| PE Ratio | 36.74 |
| Forward PE | 24.01 |
| Dividend | 0.06 (0.49%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | n/a |
| Open | 11.60 |
| Previous Close | 11.90 |
| Day's Range | 11.60 - 11.60 |
| 52-Week Range | 9.85 - 13.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 23, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial numbers in INR Financial StatementsNews
Dr. Reddy’s upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Dr. Reddy’s (RDY) to Hold from Underperform with a price target of $13.90, up from $11.40, following the September quarter EBITDA beat. The firm cites higher margins for…
Dr. Reddy’s upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Dr. Reddy’s (RDY) to Neutral from Underweight with a price target of INR 1,270, up from INR 1,100. The firm sees a more balanced risk/reward following the company’s…
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.
Dr. Reddy's Laboratories Reports Slight Revenue Dip; RDY Stock Shows 8. ...
Dr. Reddy's Laboratories Reports Slight Revenue Dip; RDY Stock Shows 8.1% Undervaluation on GF Value™
Dr. Reddy's Laboratories (RDY) Reports Q2 Earnings; Shares Trade Below GF Value™
Dr. Reddy's Laboratories (RDY) Reports Q2 Earnings; Shares Trade Below GF Value™
Dr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial Results
Dr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter ended September 30, 2026. The company reported revenues of ₹ 86,708 Mn, representing a decline of 1.5% yea...
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidom...
Dr. Reddy's Laboratories Limited Reports Revenues of Rs. 86,708 Million for the Quarter Ended September 30, 2026
Dr. Reddy's Laboratories Limited reported revenues of Rs. 86,708 million for the three months ended September 30, 2026, representing a decrease of 2% compared to Rs. 88,051 million for the three month...
Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript
Revenue declined 1.5% as Lenalidomide sales fell, but emerging markets surged 84%.
Dr. Reddy's Laboratories Transcript: Q2 26/27
Revenue declined 1.5% YoY as lower lenalidomide sales offset double-digit growth in the underlying business. Gross margin was 52.1%; management expects semaglutide validation and relaunch in November, with EBITDA margins above 20% targeted.
Dr. Reddy's Laboratories Quarterly report: Q2 2027
Dr. Reddy's Laboratories has published its Q2 2027 quarterly earnings report on October 23, 2026.
Dr. Reddy's Laboratories Slides: Q2 2027
Dr. Reddy's Laboratories has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 23, 2026.
Dr. Reddy's Laboratories Profit Drops In Q2
(RTTNews) - Friday, Dr. Reddy's Laboratories Limited (RDY) announced its financial results for the second quarter of fiscal 2027.
Dr Reddy's beats quarterly profit estimate on India market lift
Indian drugmaker Dr Reddy's Laboratories reported a better-than-expected quarterly profit on Friday, as domestic demand helped cushion the slowdown in its key US market.
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Dr Reddy's Laboratories has expanded its portfolio of generic versions of Ozempic with two new brands, according to product photographs and marketing materials reviewed by Reuters, after supply disrup...
Dr Reddy’s Labs gets CDSCO nod for Zytorvi use in esophageal squamous cell carcinoma
Dr Reddy’s gets CDSCO approval for Zytorvi (toripalimab) with chemo as first-line treatment for advanced ESCC in adults, backed by Phase 3 data.
RDY Crosses Above Key Moving Average Level
In trading on Tuesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.21, changing hands as high as $13.35 per share. Dr. Reddy's Laboratories ...
Dr. Reddy’s upgraded to Outperform from Neutral at BNP Paribas
BNP Paribas analyst Tausif Shaikh upgraded Dr. Reddy’s (RDY) to Outperform from Neutral with a $14.80 price target
Dr Reddy's, Nestle, Amazon, Flipkart Get Notice Over Misleading Health Claims
The regulator said such claims were presented on product packaging in a manner that could potentially mislead consumers about the health benefits associated with the products.
Dr. Reddy’s double-upgraded to Buy from Sell at Citi
Citi analyst Vivek Agrawal upgraded Dr. Reddy’s (RDY) to Buy from Sell with a price target of INR 1,450, up from INR 1,040. While North America revenues are expected to…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...
Top stocks to buy today: Stock market recommendations for September 22, 2026 - check list
Stock market recommendations: LIC Housing Finance, Supreme Industries, Hitachi Energy India, and Dr Reddy's Laboratories - these are the top stocks to buy on September 22, 2026 as recommended by Somil...
Dengue vaccine to hit market by first half of 2027
India News: NEW DELHI: India's first dengue vaccine is expected to be available in the private market in the first half of 2027. Takeda Pharma and Dr Reddy's Labo.
Dr Reddy’s inks pact with Takeda for rollout of dengue vaccine in India
Dr Reddy’s signs exclusive pact with Takeda to distribute dengue vaccine Qdenga in India’s private market; CDSCO approved July 2026, launch expected H1 2027.